Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Core Viewpoint - Protagonist Therapeutics reported a quarterly loss of $0.54 per share, which was better than the Zacks Consensus Estimate of a loss of $0.59, indicating an earnings surprise of 8.47% [1][2] Financial Performance - The company posted revenues of $4.68 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 3.89%, compared to zero revenues a year ago [2] - Over the last four quarters, Protagonist Therapeutics has exceeded consensus EPS estimates three times [2] Stock Performance - Protagonist Therapeutics shares have increased approximately 107.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 24.3% [3] Future Outlook - The company's earnings outlook will be crucial for determining future stock movements, with current consensus EPS estimates at $0.09 on $60.2 million in revenues for the upcoming quarter and $2.80 on $308.15 million in revenues for the current fiscal year [7] - The estimate revisions trend for Protagonist Therapeutics is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Protagonist Therapeutics belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]